Primary Hyperoxaluria Drug’s Label Receives Expansion to Include Patients with More Severe Disease
source: pixabay.com

Primary Hyperoxaluria Drug’s Label Receives Expansion to Include Patients with More Severe Disease

According to a press release published on globalgenes.org, the US Food and Drug Administration (FDA) has expanded the label for Oxlumo, a drug developed by Alnylam Pharmaceuticals as a treatment…

Continue Reading Primary Hyperoxaluria Drug’s Label Receives Expansion to Include Patients with More Severe Disease
An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Dicerna Therapeutics, Inc. has announced recently that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to…

Continue Reading An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines

What is Distal Renal Tubular Acidosis? Distal renal tubular acidosis (dRTA) is a rare condition which affects approximately 1 in every 100,000 people worldwide. It is caused by a build up…

Continue Reading Study Shows Distal Renal Tubular Acidosis Patient Outcomes Vary Across Country Lines
Ongoing Trial Investigating Autosomal Dominant Polycystic Kidney Disease Treatment
Source: Pixabay

Ongoing Trial Investigating Autosomal Dominant Polycystic Kidney Disease Treatment

An ongoing study is investigating how water intake could help treat autosomal dominant polycystic kidney disease, says a recent report. Autosomal dominant polycystic kidney disease (ADPKD) is the most common…

Continue Reading Ongoing Trial Investigating Autosomal Dominant Polycystic Kidney Disease Treatment